Compare Recursion Pharmaceuticals Inc (RXRX) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B), while Vanguard Information Technology Index Fund ETF trades at $121.62. The key difference: Vanguard Information Technology Index Fund ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | VGT | |
|---|---|---|
Market Cap | $1.81B | — |
Sector | Health | — |
52-Week High | $6.79 | $125.77 |
52-Week Low | $2.84 | $83.59 |
Enterprise Value | $1.33B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
VGT trades at $121.35, up 0.91% today, with a bullish technical outlook supported by moving averages but neutral oscillators. The ETF's pure-play technology focus, driven by AI infrastructure exposure, has attracted significant institutional buying, as seen in recent SEC filings. Recent news highlights strong performance relative to broader tech ETFs, with key holdings like Microsoft and Nvidia fueling gains.
Outlook remains positive due to AI-driven capital expenditure trends, though concentration risk in top holdings and potential sector volatility pose challenges. The ETF's low-cost structure and momentum position it for continued growth, but investors should monitor semiconductor cyclicality and broader market sentiment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
